Inactive Instrument

Other languages Jaguar Health Inc Nasdaq

Equities

US47008L1061

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	05-06
Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	05-06
Venture Life renews revolving credit facility with Santander and HSBC	04-19
Jaguar Health, Inc. Appoints Catherine Miller Collis to the Role of Senior Vice President of Growth Strategy	04-18
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	04-10
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	04-10
Top Premarket Gainers	04-10
Jaguar Health, Inc. Appoints Massimo Radaelli, PhD, as President of Jaguar International	04-03
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	02-15
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	02-15
Top Premarket Gainers	01-26
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	12-11
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	12-04
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	11-21
Sector Update: Health Care Stocks Rise Tuesday Afternoon	11-21
Jaguar Health's Napo Pharmaceuticals Awaits Data on Phase 3 Trial of Crofelemer; Shares Fall	11-21
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	11-08
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	11-01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Jaguar Health Inc Nasdaq

Equities

US47008L1061

Other languages

Filters